Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Susanna Price,
View the Slides from this session in ESC Congress 365
This session provided a fascinating insight into the evolving world of mechanical circulatory support in extreme cardiogenic shock.
It began with an overview from Professor Leprince regarding the temporary devices currently available for the full range of potential clinical scenarios in the acute setting, including the emerging use of ECMO and EMCO-CPR. The important finding that concomitant IABP+ECMO offloads the LV was discussed, suggesting it be routine for peripheral ECMO.
Professor Jessup focused on the use of isolated LVAD in patients with cardiogenic shock, outlining some of the classifications and definitions which clincians involved in VADs are required to utilize, highlighting the importance of early referral, as well as the critical requirement for concomitant right ventricular assessment. Adverse outcomes from VAD were discussed, reiterating the superior outcome from transplantation compared with any currently available mechanical device.
Professor Potapov described the importance and challenges regarding acute and ongoing RV assessment in the era of modern continuous flow devices, as well as treatment options in the context of persistent biventricular failure. The overriding message from all three initial speakers was of the importance of timely and appropriate assessment and referral.
Finally, Professor Carpentier described his 30-year collaborative enterprise, leading to the evolution of the first bioprosthetic totally implantable heart, with the first implantation in a human subject as part of a preliminary study occurring in 2013. Professor Carpentier ended his presentation by paying homage to patients who participate in such innovative clinical trials, describing them as the “real heroes of medical progress”.
Update on mechanical circulatory support